As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Neurogene Inc. The largest reported stake is Prudential Financial Inc's, at 11.2%. 10 filings are on record since August 14, 2025 (Schedule 13G, October 7, 2026).
Sell to companies like Neurogene Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Prudential Financial Inc · Sole voting: 0 · Shared voting: 1,791,746 · Sole dispositive: 0 · Shared dispositive: 2,231,357 · SCHEDULE 13G, 2026-10-07
- · Reporting person: Jennison Associates LLC · Sole voting: 2,229,082 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 2,229,082 · SCHEDULE 13G, 2026-10-06
- · Reporting person: Redmile Group, LLC · Sole voting: 0 · Shared voting: 1,572,202 · Sole dispositive: 0 · Shared dispositive: 1,572,202 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Balyasny Asset Management L.P. · Sole voting: 818,706 · Shared voting: 0 · Sole dispositive: 818,706 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Trails Edge Capital Partners, LP · Sole voting: 714,885 · Shared voting: 0 · Sole dispositive: 714,885 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
Neurogene Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-14. 6 holders' latest filing reports 5% or more of common. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Prudential Financial Inc | 11.2% | 2,231,357 | SCHEDULE 13G, 2026-10-07 | 2026-09-30 |
| Jennison Associates LLC | 11.1% | 2,229,082 | SCHEDULE 13G, 2026-10-06 | 2026-09-30 |
| EcoR1 Capital, LLC | 9.9% | 1,442,902 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Redmile Group, LLC | 9.9% | 1,572,202 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Baker Bros. Advisors LP | 7% | 991,691 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Balyasny Asset Management L.P. | 5.18% | 818,706 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Trails Edge Capital Partners, LP | 4.5% | 714,885 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Commodore Capital LP | 3% | 427,866 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Neurogene Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Neurogene Inc. and the records around it.
Neurogene Inc. elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Nurix Therapeutics, Inc. (Aug 2026)
Watch Neurogene Inc.
Get an email when Neurogene Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neurogene Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Neurogene Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neurogene Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Prudential Financial Inc | 0 | 1,791,746 | 0 | 2,231,357 | SCHEDULE 13G, 2026-10-07 |
| Jennison Associates LLC | 2,229,082 | 0 | 0 | 2,229,082 | SCHEDULE 13G, 2026-10-06 |
| Redmile Group, LLC | 0 | 1,572,202 | 0 | 1,572,202 | SCHEDULE 13G/A, 2026-08-14 |
| Jeremy C. Green | 0 | 1,572,202 | 0 | 1,572,202 | SCHEDULE 13G/A, 2026-08-14 |
| Redmile Biopharma Investments I, L.P. | 0 | 812,033 | 0 | 812,033 | SCHEDULE 13G/A, 2026-08-14 |
| Balyasny Asset Management L.P. | 818,706 | 0 | 818,706 | 0 | SCHEDULE 13G, 2026-08-14 |
| Bam Gp LLC | 818,706 | 0 | 818,706 | 0 | SCHEDULE 13G, 2026-08-14 |
| Balyasny Asset Management Holdings LP | 818,706 | 0 | 818,706 | 0 | SCHEDULE 13G, 2026-08-14 |
| Dames GP LLC | 818,706 | 0 | 818,706 | 0 | SCHEDULE 13G, 2026-08-14 |
| Dmitry Balyasny | 818,706 | 0 | 818,706 | 0 | SCHEDULE 13G, 2026-08-14 |
| Trails Edge Capital Partners, LP | 714,885 | 0 | 714,885 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Trails Edge Biotechnology Master Fund, LP | 714,885 | 0 | 714,885 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Ortav Yehudai | 714,885 | 0 | 714,885 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Neurogene Inc. by CUSIP 64135M105 and gives its principal executive office as 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY 10011 (SCHEDULE 13G, 2026-10-07).
What the percentages are based on
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 5.18% of the Shares, based on 15,801,901 Shares outstanding as of May 8, 2026, as reported in the Issuer's Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026. The report amount consists of 818,706 Shares.Balyasny Asset Management L.P., SCHEDULE 13G, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Baker Bros. Advisors LP | 7% | SCHEDULE 13G/A |
| 2025-08-14 | Commodore Capital LP | 3% | SCHEDULE 13G/A |
| 2025-11-14 | EcoR1 Capital, LLC | 9.9% | SCHEDULE 13G/A |
| 2025-12-15 | Trails Edge Capital Partners, LP | 5.1% | SCHEDULE 13G |
| 2026-02-17 | Redmile Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-08-14 | Redmile Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-08-14 | Balyasny Asset Management L.P. | 5.18% | SCHEDULE 13G |
| 2026-08-14 | Trails Edge Capital Partners, LP | 4.5% | SCHEDULE 13G/A |
| 2026-10-06 | Jennison Associates LLC | 11.1% | SCHEDULE 13G |
| 2026-10-07 | Prudential Financial Inc | 11.2% | SCHEDULE 13G |
Questions about who owns Neurogene Inc.
Who owns Neurogene Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Neurogene Inc.: Prudential Financial Inc (11.2%, Schedule 13G, filed 2026-10-07), Jennison Associates LLC (11.1%, Schedule 13G, filed 2026-10-06), EcoR1 Capital, LLC (9.9%, Schedule 13G/A, filed 2025-11-14), Redmile Group, LLC (9.9%, Schedule 13G/A, filed 2026-08-14) and Baker Bros. Advisors LP (7%, Schedule 13G/A, filed 2025-08-14); 1 more is listed above.
Who are the largest shareholders of Neurogene Inc.?
By the share each holder's latest filing reports, the largest holders of Neurogene Inc. on this page are Prudential Financial Inc (11.2%), Jennison Associates LLC (11.1%) and EcoR1 Capital, LLC (9.9%).
When did Prudential Financial Inc buy into Neurogene Inc.?
The filings give report dates, not purchase dates. The earliest filing from Prudential Financial Inc on this page is the Schedule 13G, filed 2026-10-07, reporting 11.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Neurogene Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 20, 2026 | Leadership change: Christine Mikail appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Neurogene Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.